# Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

> **NCT01480219** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 467 (actual)

## Conditions studied

- Non-Melanoma Skin Carcinoma

## Interventions

- **DRUG:** voriconazole (Vfend)
- **OTHER:** no voriconazole (Vfend)

## Key facts

- **NCT ID:** NCT01480219
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2013-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480219, "Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01480219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*